Ann Rheum Dis:SLE疾病活动性评分(SLE-DAS)的推导和验证

2019-01-10 xiangting MedSci原创

SLE-DAS具有良好的结构有效性,并且在识别疾病活动性临床显著变化和预测损伤方面优于SLEDAI-2K。

这项研究旨在推导和验证一种新的系统性红斑狼疮(SLE)疾病活动性指标,即SLE疾病活动性评分(SLE-DAS)。该评分与SLE疾病活动指数(SLEDAI)相比,在保持高度特异性的同时,对变化的敏感性更高,并简单好用。

研究了来自2个三级医疗中心(推导和验证队列)的520名SLE患者。在每次就诊时,使用医师整体评估(PGA)和SLEDAI 2000(SLEDAI-2K)对疾病活动性进行评分。为了构建SLE-DAS,研究人员在推导队列中应用多元线性回归分析,以PGA作为因变量。该公式通过以下研究在另一个队列中进行验证:(1)SLE-DAS、PGA和SLEDAI-2K之间的相关性;(2)SLEDAI-2K和SLE-DAS在识别疾病活动性有临床意义的变化方面的表现(ΔPGA≥0.3);(3)SLEDAI-2K和SLE-DAS时间调整均值在预测损伤中的准确性。

最终的SLE-DAS包括17项。在验证队列中,SLE-DAS与PGA(r=0.875,p<0.0005)和SLEDAI-2K(r=0.943,p<0.0005)高度相关。ΔSLE-DAS检测临床有意义变化的最佳辨别阈值为1.72。在验证队列中,SLE-DAS在检测临床有意义的改善(89.5%vs 47.4%,p=0.008)或恶化(95.5%vs 59.1%,p=0.008)方面比SLEDAI-2K(变化≥4)的敏感性更高,同时保持了相似的特异性。SLE-DAS在预测损伤方面比SLEDAI-2K表现更好。

SLE-DAS具有良好的结构有效性,并且在识别疾病活动性临床显著变化和预测损伤方面优于SLEDAI-2K。

原始出处:

Diogo Jesus. Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity. Ann Rheum Dis. 09 January 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2070880, encodeId=0b5820e08804b, content=<a href='/topic/show?id=08c8e06964f' target=_blank style='color:#2F92EE;'>#疾病活动性评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70696, encryptionId=08c8e06964f, topicName=疾病活动性评分)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Sun Jul 28 16:09:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690856, encodeId=00a31690856e1, content=<a href='/topic/show?id=4a49e0695f2' target=_blank style='color:#2F92EE;'>#疾病活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70695, encryptionId=4a49e0695f2, topicName=疾病活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6bf29152327, createdName=hukaixun, createdTime=Thu Sep 12 18:09:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723956, encodeId=03a91e2395685, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Sun May 19 19:09:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756068, encodeId=683c1e5606825, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Thu Jun 06 22:09:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012908, encodeId=901320129085a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jan 31 12:09:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345006, encodeId=d06e134500684, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Sat Jan 12 01:09:00 CST 2019, time=2019-01-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2070880, encodeId=0b5820e08804b, content=<a href='/topic/show?id=08c8e06964f' target=_blank style='color:#2F92EE;'>#疾病活动性评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70696, encryptionId=08c8e06964f, topicName=疾病活动性评分)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Sun Jul 28 16:09:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690856, encodeId=00a31690856e1, content=<a href='/topic/show?id=4a49e0695f2' target=_blank style='color:#2F92EE;'>#疾病活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70695, encryptionId=4a49e0695f2, topicName=疾病活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6bf29152327, createdName=hukaixun, createdTime=Thu Sep 12 18:09:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723956, encodeId=03a91e2395685, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Sun May 19 19:09:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756068, encodeId=683c1e5606825, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Thu Jun 06 22:09:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012908, encodeId=901320129085a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jan 31 12:09:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345006, encodeId=d06e134500684, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Sat Jan 12 01:09:00 CST 2019, time=2019-01-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2070880, encodeId=0b5820e08804b, content=<a href='/topic/show?id=08c8e06964f' target=_blank style='color:#2F92EE;'>#疾病活动性评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70696, encryptionId=08c8e06964f, topicName=疾病活动性评分)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Sun Jul 28 16:09:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690856, encodeId=00a31690856e1, content=<a href='/topic/show?id=4a49e0695f2' target=_blank style='color:#2F92EE;'>#疾病活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70695, encryptionId=4a49e0695f2, topicName=疾病活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6bf29152327, createdName=hukaixun, createdTime=Thu Sep 12 18:09:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723956, encodeId=03a91e2395685, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Sun May 19 19:09:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756068, encodeId=683c1e5606825, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Thu Jun 06 22:09:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012908, encodeId=901320129085a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jan 31 12:09:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345006, encodeId=d06e134500684, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Sat Jan 12 01:09:00 CST 2019, time=2019-01-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2070880, encodeId=0b5820e08804b, content=<a href='/topic/show?id=08c8e06964f' target=_blank style='color:#2F92EE;'>#疾病活动性评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70696, encryptionId=08c8e06964f, topicName=疾病活动性评分)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Sun Jul 28 16:09:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690856, encodeId=00a31690856e1, content=<a href='/topic/show?id=4a49e0695f2' target=_blank style='color:#2F92EE;'>#疾病活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70695, encryptionId=4a49e0695f2, topicName=疾病活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6bf29152327, createdName=hukaixun, createdTime=Thu Sep 12 18:09:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723956, encodeId=03a91e2395685, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Sun May 19 19:09:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756068, encodeId=683c1e5606825, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Thu Jun 06 22:09:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012908, encodeId=901320129085a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jan 31 12:09:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345006, encodeId=d06e134500684, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Sat Jan 12 01:09:00 CST 2019, time=2019-01-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2070880, encodeId=0b5820e08804b, content=<a href='/topic/show?id=08c8e06964f' target=_blank style='color:#2F92EE;'>#疾病活动性评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70696, encryptionId=08c8e06964f, topicName=疾病活动性评分)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Sun Jul 28 16:09:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690856, encodeId=00a31690856e1, content=<a href='/topic/show?id=4a49e0695f2' target=_blank style='color:#2F92EE;'>#疾病活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70695, encryptionId=4a49e0695f2, topicName=疾病活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6bf29152327, createdName=hukaixun, createdTime=Thu Sep 12 18:09:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723956, encodeId=03a91e2395685, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Sun May 19 19:09:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756068, encodeId=683c1e5606825, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Thu Jun 06 22:09:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012908, encodeId=901320129085a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jan 31 12:09:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345006, encodeId=d06e134500684, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Sat Jan 12 01:09:00 CST 2019, time=2019-01-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2070880, encodeId=0b5820e08804b, content=<a href='/topic/show?id=08c8e06964f' target=_blank style='color:#2F92EE;'>#疾病活动性评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70696, encryptionId=08c8e06964f, topicName=疾病活动性评分)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Sun Jul 28 16:09:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690856, encodeId=00a31690856e1, content=<a href='/topic/show?id=4a49e0695f2' target=_blank style='color:#2F92EE;'>#疾病活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70695, encryptionId=4a49e0695f2, topicName=疾病活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6bf29152327, createdName=hukaixun, createdTime=Thu Sep 12 18:09:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723956, encodeId=03a91e2395685, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Sun May 19 19:09:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756068, encodeId=683c1e5606825, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Thu Jun 06 22:09:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012908, encodeId=901320129085a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jan 31 12:09:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345006, encodeId=d06e134500684, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Sat Jan 12 01:09:00 CST 2019, time=2019-01-12, status=1, ipAttribution=)]

相关资讯

J Rheumatol:使用共识方法确定系统性红斑狼疮分类标准的候选项目

专家组NGT产生了21条候选SLE分类标准。SLE分类标准制定的下一阶段将需要标准定义的改进。

Semin Arthritis Rheu:贝利木单抗治疗的SLE患者低疾病活动性与皮质类固醇减量和发作次数减少相关

在现实生活中,超过40%的未选择患者在贝利木单抗治疗后实现了低疾病活动性,同时皮质类固醇减量和发作次数减少。

Semin Arthritis Rheu:在系统性红斑狼疮诊断时预测狼疮性肾炎的最终发展

SLE诊断时的年龄小、C3低、抗dsDNA滴度高、存在抗Sm抗体与未来出现狼疮性肾炎的风险相关,但AGR数值低的危害最大。

Arthritis Rheumatol:奥马珠单抗治疗系统性红斑狼疮的安全性和耐受性(STOP LUPUS)

奥马珠单抗治疗SLE具有良好的耐受性,并与疾病活动性改善相关。

常见风湿病中糖皮质激素的正确用法,你都知道吗?

糖皮质激素具有广泛抗炎、免疫抑制作用。风湿病病友惧怕它,但有许多病友在不知情的情况下已经用了糖皮质激素。偏方、广告神药以及所谓的特效药当中往往被偷偷添加的糖皮质激素,使用一段时间之后会发现药物越来越差,体型也出现了上面字谜描述的变化。

Ann Rheum Dis:贝利木单抗与标准治疗的器官损害比较

与接受SoC治疗的患者相比,贝利木单抗治疗的PS匹配患者器官损害的进展明显更少。